After 22 years without a viable option, LB6V represents the first Lyme disease vaccine candidate to advance significantly toward FDA approval. The breakthrough offers hope to millions who face tick-borne infection risks.
22 years Years since previous vaccine withdrawal
First To Advance This Far Since 2002 Vaccine development milestone
22 Years years since last vaccine